CLSD vs. LFVN, IMMP, ITOS, AQST, CMPX, OLMA, ATYR, RZLT, NGNE, and AVIR
Should you be buying Clearside Biomedical stock or one of its competitors? The main competitors of Clearside Biomedical include LifeVantage (LFVN), Immutep (IMMP), iTeos Therapeutics (ITOS), Aquestive Therapeutics (AQST), Compass Therapeutics (CMPX), Olema Pharmaceuticals (OLMA), Atyr PHARMA (ATYR), Rezolute (RZLT), Neurogene (NGNE), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.
Clearside Biomedical vs.
LifeVantage (NASDAQ:LFVN) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, community ranking, dividends, earnings, institutional ownership and analyst recommendations.
LifeVantage has higher revenue and earnings than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
LifeVantage presently has a consensus price target of $30.50, suggesting a potential upside of 20.51%. Clearside Biomedical has a consensus price target of $5.33, suggesting a potential upside of 473.54%. Given Clearside Biomedical's higher possible upside, analysts plainly believe Clearside Biomedical is more favorable than LifeVantage.
LifeVantage has a net margin of 2.11% compared to Clearside Biomedical's net margin of -413.83%. LifeVantage's return on equity of 29.24% beat Clearside Biomedical's return on equity.
Clearside Biomedical received 145 more outperform votes than LifeVantage when rated by MarketBeat users. However, 77.97% of users gave LifeVantage an outperform vote while only 67.28% of users gave Clearside Biomedical an outperform vote.
In the previous week, LifeVantage had 16 more articles in the media than Clearside Biomedical. MarketBeat recorded 17 mentions for LifeVantage and 1 mentions for Clearside Biomedical. Clearside Biomedical's average media sentiment score of 1.45 beat LifeVantage's score of 0.60 indicating that Clearside Biomedical is being referred to more favorably in the news media.
LifeVantage has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500.
35.3% of LifeVantage shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 20.7% of LifeVantage shares are held by company insiders. Comparatively, 9.2% of Clearside Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
LifeVantage beats Clearside Biomedical on 11 of the 17 factors compared between the two stocks.
Get Clearside Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLSD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Clearside Biomedical Competitors List
Related Companies and Tools
This page (NASDAQ:CLSD) was last updated on 1/20/2025 by MarketBeat.com Staff
